<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01283061</url>
  </required_header>
  <id_info>
    <org_study_id>BA0759156</org_study_id>
    <nct_id>NCT01283061</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioavailability Study Of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of 'ACCOLATE' Tablets 20 mg of Astrazeneca Pharmaceuticals, USA In Healthy Adult Human Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the relative bioavailability of zafirlukast&#xD;
      tablets 20 mg with that of 'ACCOLATEÂ®' tablets 20 mg (zafirlukast tablets 20 mg) in healthy,&#xD;
      adult, human, subjects under fasting conditions and to monitor safety of subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      open label, randomized, two-period, two treatment, two sequence, crossover, balanced single&#xD;
      dose comparative oral bioavailability study in healthy, adult, human subjects under fasting&#xD;
      conditions.44 healthy, adult, human subjects.There was 11-day interval between treatments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence on Cmax and AUC parameters</measure>
    <time_frame>13 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>zafirlukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zafirlukast Tablets 20 mg of Dr. Reddys Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Accolate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACCOLATE tablets manufactured by IPR pharmaceuticals and manufactured for Astrazeneca Pharmaceuticals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zafirlukast</intervention_name>
    <description>Zafirlukast tablets 20 mg</description>
    <arm_group_label>Accolate</arm_group_label>
    <arm_group_label>zafirlukast</arm_group_label>
    <other_name>Accolate tablets 20 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subjects should be healthy human between 18 and 45 years.&#xD;
&#xD;
          2. The subjects should be screened within 21 days prior to the administration of first&#xD;
             dose of the study drug.&#xD;
&#xD;
          3. The subjects should have a BMI between 18.5 and 24.9 weight in kg/ height2 in meter.&#xD;
&#xD;
          4. The subjects should be able to communicate effectively with study personnel.&#xD;
&#xD;
          5. The subjects should be able to give written informed consent to participate in the&#xD;
             study.&#xD;
&#xD;
             If subject is a female volunteer and&#xD;
&#xD;
          6. Is of child bearing potential practicing an acceptable method of birth control for the&#xD;
             duration of the study as judged by the investigator(s), such as condoms,foams,&#xD;
             jellies, diaphragm, intrauterine device (IUD), or abstinence.&#xD;
&#xD;
          7. Is postmenopausal for at least 1 year.&#xD;
&#xD;
          8. Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
             hysterectomy has been performed on the subject).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subjects who have a history of allergic responses to zafirlukast or other related&#xD;
             drugs.&#xD;
&#xD;
          2. The subjects who have used enzyme-modifying drugs within 30 days prior to receiving&#xD;
             the first dose of study medication.&#xD;
&#xD;
          3. The subjects who have history of drug dependence, recent history of alcoholism or of&#xD;
             moderate alcohol uses.&#xD;
&#xD;
          4. The subjects who have significant diseases or clinically significant abnormal findings&#xD;
             during screening, medical history, physical examination, laboratory evaluations, ECG&#xD;
             and X-ray recordings.&#xD;
&#xD;
          5. The subjects who have any disease or condition which might compromise the&#xD;
             haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central&#xD;
             nervous system, diabetes, psychosis or any other body system.&#xD;
&#xD;
          6. The subjects who have a history or presence of bronchial asthma&#xD;
&#xD;
          7. The subjects who are smokers who smoke more than or equal to 10 cigarettes per day or&#xD;
             more than or equal to 20 biddies per day or those who cannot refrain from smoking&#xD;
             during study period.&#xD;
&#xD;
          8. The subjects with a history of difficulty with donating blood or difficulty in&#xD;
             accessibility of veins.&#xD;
&#xD;
          9. The subjects who have donated 1 unit (350 ml / 450 ml) blood within 90 days prior to&#xD;
             receiving the first dose of study medication.&#xD;
&#xD;
         10. The subjects who have a positive hepatitis screen (includes subtypes A, B, C and E)&#xD;
&#xD;
         11. The subjects who have a positive test result for HIV antibody and / or&#xD;
             syphilis(RPR/VDRL).&#xD;
&#xD;
         12. The subject who receives an investigational product, or has participated in a drug&#xD;
             research study within a period of 90 days prior to the first dose of the study&#xD;
             medication administration.&#xD;
&#xD;
         13. Female volunteers demonstrating a positive pregnancy screen.&#xD;
&#xD;
         14. Female volunteers who are currently breast-feeding.&#xD;
&#xD;
         15. Female volunteers not willing to use contraception during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronak Modi, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>BA Research India Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BA Research India Ltd.</name>
      <address>
        <city>Ahmedabad</city>
        <state>Bodakdev</state>
        <zip>380 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>January 24, 2011</study_first_submitted>
  <study_first_submitted_qc>January 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2011</study_first_posted>
  <last_update_submitted>January 25, 2011</last_update_submitted>
  <last_update_submitted_qc>January 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director-Research &amp; Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zafirlukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

